The moves come as Bayer seeks approval from Berkeley leaders for a new 30-year master plan that would allow the Germany-based company to build 1 million square feet of production, research and office space and add some 1,000 employees over that period.
At the forefront of Bayer's big plans are cell therapies, which employ genetically engineered cells to fix blood cancers and potentially more diseases, and one-shot-and-done gene therapies that insert a correct copy of a gene to replace a defective, disease-causing gene.
By Gaia Ghirardi, Arno Van Hootegem & K. Paige Harden , Nature Human Behaviour | 09.21.2026
Aggregated News
Embryo screening for behavioural traits is no longer speculative. If you want to become a parent in the USA today, you can pay to use pre-implantation polygenic testing (PGT-P) of in vitro fertilization (IVF)-created embryos. PGT-P promises to optimize offspring...
What We Inheritby Sam Trejo and Daphne O. Martschenko; andOriginal Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
NEW YORK (AP) — Matt Walker couldn’t pet a dog without sneezing — until he and other scientists used a gene editing technique to produce a hypoallergenic beagle named Bailey.
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
